Objective: To illustrate the application of the Consensus on the Rational Use of Antithrombotics in Veterinary Critical Care (CURATIVE) guidelines to the management of dogs and cats at risk of developing thrombosis using a case-based approach.
INTRODUCTION
Following the development of the first consensus guidelines for the rational use of antithrombotics in dogs and cats at risk of thrombosis, 1 the Consensus working group created a series of clinical cases that could be used to demonstrate how guideline recommendations could be applied. The body of work conducted as part of the Consensus on the Rational Use of Antithrombotics in Veterinary Critical Care (CURATIVE) initiative encompasses a summary of the guidelines, 1 as well as the individual domain manuscripts that provided the Population/Patient, Intervention, Control, Outcome (PICO) questions and evidence summaries used to generate the guidelines. [2] [3] [4] [5] [6] The aim of this manuscript is to provide additional direction on the practical application of these guidelines.
The CURATIVE recommendations are intended for the "average" dog or cat at risk of thrombosis, receiving care in a "typical" veterinary emergency and critical care practice or specialty hospital. Nonetheless, the CURATIVE contributors recognize that there is considerable variation in clinical cases presenting to veterinarians and in the practice settings in which these guidelines may be applied. As such, the objective of this manuscript is to provide a discursive illustration of the application of the guidelines to the management of dogs and cats at risk for thrombosis using a case-based approach.
Cases scenarios were developed based on populations at risk of thrombosis as outlined in CURATIVE Domain 1. 2 Case descriptions were left deliberately vague to encompass a variety of different disease presentations and severities. Therapeutic recommendations for dogs and cats were tailored to specific case vignettes based on the CURATIVE guidelines regarding antithrombotic drug choices and dosing protocols, as outlined in Domains 2 and 3. 3, 4 Where appropriate, guidelines describing therapeutic monitoring (Domain 4) 5 and discontinuation of antithrombotics (Domain 5) 6 were included. The CURATIVE contributors from 4 different geographic areas (the US, Canada, the UK, and Australia) provided information regarding drug formulations available to them with the estimated costs for each antithrombotic drug. Specific information regarding pricing was avoided, rather a general estimate is provided to illustrate the potential financial implications of different therapies for the pet owner. Not all of the antithrombotic drugs discussed in the CURATIVE guidelines will be available in all in-house veterinary hospital pharmacies, thus some cost estimates are based on prices from human pharmacies. Clinicians are encouraged to seek out local information when prescribing specific antithrombotic therapies.
It should also be noted that these case scenarios do not include mention of thrombolytic therapies. Some specialists in veterinary emergency and critical care, and allied specialists that treat patients with thrombosis, may consider the use of thrombolytic drugs in some of the case scenarios provided herein. Since the use of thrombolytics in dogs and cats was outside the scope of the CURATIVE guidelines, such therapies are not addressed in this manuscript.
Case scenario 1 -A dog with immune-mediated hemolytic anemia
A 6-year-old, 8 kg, female neutered Shih Tzu is diagnosed with immunemediated hemolytic anemia (IMHA) based on the presence of severe anemia, spherocytosis, a positive saline agglutination test, and evidence of extravascular hemolysis (hyperbilirubinemia). No identifiable cause was found despite an extensive diagnostic evaluation and as such the dog was considered to have primary IMHA. Treatment included immunosuppressive medications, packed red blood cell transfusion, and symptomatic care.
Application of the CURATIVE guidelines
Immune-mediated hemolytic anemia is strongly associated with the development of thrombosis in dogs and as such antithrombotic therapy is recommended in this patient (Guideline There is insufficient evidence to make strong recommendations regarding the choice of antiplatelet agent in dogs, but we suggest that clopidogrel may be more effective than aspirin in dogs at risk of arterial thromboembolism (ATE) (Guideline 2.5). Dual antiplatelet therapy could also be considered; however, this was not specifically addressed in the CURATIVE guidelines.
Information regarding the aforementioned antithrombotic drugs, their dosing regimen, and approximate costs of therapy for this dog are provided in to administer the required dose from an individual dose syringe, and discard the remainder. It may be more practical to aseptically decant the contents of the syringe into a sterile vial, from which subsequent doses can be removed with a needle and syringe. The authors suggest that clinicians consult with their local pharmacy on the optimal method to achieve this in their practice setting. 
Case scenario 2a -Aortic thrombosis in a dog with protein losing nephropathy

Application of the CURATIVE guidelines
Protein losing nephropathy is reliably associated with the development of thrombosis in dogs (Guideline 1.2a). Specifically, dogs with PLN are defined as being at high risk for thrombosis (Guideline 1.11).
The CURATIVE guidelines recommend antithrombic therapy for dogs with PLN (Guideline 1.2b). We suggest that antiplatelet agents may be more effective than anticoagulants for the prevention of ATE in dogs (Guideline 2.3a), but nonetheless, we suggest that anticoagulants may also be effective for the prevention of ATE in dogs (Guideline 2.3b).
Although there is insufficient evidence to make strong recommendations regarding clopidogrel versus aspirin in dogs (Guideline 2.5a), the CURATIVE group suggests that clopidogrel may be more effective than aspirin in dogs at risk of ATE (Guideline 2.5b). New antiplatelet agents could also be considered given evidence of favorable safety and efficacy (Guideline 2.7). Although this dog already has a diagnosed ATE, the same recommendations seem reasonable to apply as for ATE prevention. Approach to the thrombus itself is outside the scope of the CURATIVE guidelines; the reader is directed to recent literature. 9 There is insufficient evidence to make strong recommendations for or against the use of combination antiplatelet and anticoagulant therapy in dogs at risk of ATE (Guideline 2.19a). We suggest that combination antiplatelet and anticoagulant therapy can be considered when the risk of thrombosis is felt to outweigh the increased risk of bleeding resulting from combination therapy (Guideline 2.17). We suggest that the administration of clopidogrel or aspirin with LMWH may be considered in dogs at risk for ATE (Guideline 2.19b). With regard to the choice of anticoagulant in dogs, we suggest that the direct Xa inhibitors or LMWH may be used in preference to UFH (Guidelines 2.9b and 2.11b).
Warfarin is not recommended (Guideline 3.5). Information regarding the aforementioned antithrombotic drugs, their dosing regimen, and approximate costs of therapy for this dog are provided in Table 2 .
Therapeutic monitoring would not be recommended for this dog unless a LMWH is selected as the anticoagulant. We suggest that adjusting therapy in dogs, targeting anti-Xa activity of 0.5-1.0 U/mL 2-4 hours post-dose can be considered (Guideline 4.4b).
Antithrombotic therapy would be a lifelong recommendation in this dog, since the underlying condition cannot be cured or resolved (Guideline 5.11b), even after resolution of the thrombus.
Case scenario 2b -A dog receiving antithrombotic drugs now requires surgery
Twelve months later the same dog described in case scenario 2a, now recovered from ATE, returns to the emergency room for evaluation of lethargy and inappetence. He is receiving clopidogrel and enoxaparin in addition to his GN specific therapies. Screening diagnostics reveal a large cavitated mass at the tail of the spleen with a small volume of echogenic peritoneal effusion, confirmed to be hemorrhage after aspiration and fluid analysis. The owners are keen to pursue a splenectomy given the high risk of the mass being neoplastic 10 ; nonetheless the dog is cardiovascularly stable and it is considered that splenectomy may not need to be performed immediately. Attention is given as to whether the antithrombotic therapy should be discontinued prior to surgery.
Application of the CURATIVE guidelines
This dog is considered a high risk for thrombosis based on his history of PLN and prior aortic thrombosis (Guideline 1.11). As such, we recommend that antiplatelet therapy with a single antiplatelet agent (in this case, clopidogrel) be continued prior to an elective procedure (ie, not discontinued) (Guideline 5.2a).
Similarly, we recommend that LMWH therapy should not be discontinued prior to an elective procedure. We recommend that surgery should be planned to occur at the nadir of the anticoagulant effect (Guideline 5.4), which is likely to occur just prior to the next scheduled dose (ie, 12 h after the previous enoxaparin dose when administered at q12 hour intervals). The surgery team should be prepared for an increased risk of bleeding due to treatment with clopidogrel and LMWH, and close attention should be paid to surgical hemostasis, including the use of electrocautery. Appropriate ancillary diagnostic tests (eg, blood type, or crossmatch if indicated) should be performed prior to surgery in anticipation of potential need of blood product transfusion, and non-steroidal anti-inflammatory drugs should be avoided as part of the analgesic regimen due to potential adverse effects on platelet function.
In the situation where surgery on a patient receiving both antiplatelet and antithrombotic medications is not desired, consideration may be given to partial discontinuation of therapy prior to the procedure. Because abrupt discontinuation of LWMH is not associated with a rebound prothrombotic state (Guideline 5.14), and because the dog primarily had an arterial thrombotic event, it can be considered to continue clopidogrel therapy through the surgical period and discontinue LMWH for the perioperative period, with a recognition that the dog may be at a higher risk for the development of perioperative thrombosis.
After surgery, we recommend that antithrombotic therapy is continued on the same schedule, or restarted as soon as possible, provided there is no evidence of ongoing bleeding, since this patient is considered to be at high risk for thrombosis due to the underlying PLN and prior history of thrombosis (Guideline 5.8). Thrombosis is also reported to be a complication that can occur after splenectomy in dogs. 11 
Case scenario 3 -A dog with sepsis
Application of the CURATIVE guidelines
Sepsis is associated with derangements in coagulation, including disseminated intravascular coagulation and less commonly macrothrombosis. 2 In veterinary medicine there is insufficient evidence at this time to recommend the routine use of antithrombotics in dogs with sepsis (Guideline 1.7a, b) . The clinician could consider performing viscoelastic testing as a global evaluation of coagulation.
Antithrombotic therapy may be considered for dogs with sepsis where hypercoagulability is demonstrated (Guideline 1.7c) or where other risk factors including co-morbidities or drug therapies exist.
Case scenario 4 -A dog with hyperadrenocorticism and pancreatitis
An 8-year-old, male neutered, mixed breed dog (body weight 8 kg) is hospitalized for a 3-day history of vomiting and anorexia. 15) . In this case, the administration of aspirin or clopidogrel in addition to LMWH or a direct Xa inhibitor is not recommended, as the risk of clot formation is unlikely to outweigh the increased risk of bleeding resulting from combination therapy (Guideline 2.17).
TA B L E 2 Estimated costs of antithrombotic drug options for a 30 kg Labrador Retriever with protein losing nephropathy and aortic thromboembolism
Information regarding a two-week course of LMWH or a direct Xa inhibitor is provided in Table 3 . Therapeutic monitoring could be considered for this dog if LMWH was chosen as the antithrombotic drug of choice. We suggest that adjusting therapy in dogs, targeting antiXa activity of 0.5-1.0 U/mL 2-4 hours post-dose can be considered (Guideline 4.4b).
Antithrombotic therapy would only be a short-term recommendation in this dog, since one of the underlying conditions (pancreatitis) can completely resolve with treatment (Guideline 5.12).
Although there is insufficient evidence to make specific recommendations regarding the duration of antithrombotic treatment, a two-week course of antithrombotics is likely to be adequate. Alternatively, the clinician could consider discontinuation based on ultrasonographic evidence of resolution of disease. Since clinical signs often resolve prior to resolution of pancreatic inflammation, it is possible that the risk period for thrombosis continues beyond resolution of clinical signs, and thus so should antithrombotic therapy. Using blood-based biomarkers of systemic inflammation such as C-reactive protein, may also be useful. 14 If LMWH was chosen as the antithrombotic, weaning prior to discontinuation is not recommended (Guideline 5.14). If rivaroxaban was chosen as the antithrombotic, weaning can be considered (Guideline
5.15).
For this particular patient, a rivaroxaban dosing schedule of one 10 mg tablet once a day for two weeks, followed by one half tablet once a day for two days, followed by one half tablet every other day for two doses, then discontinuation, would be a reasonable approach. The left atrium is enlarged (left atrial: aortic ratio 1.8 [normal < 1.6]). 15 A thyroid panel is performed to rule out thyrotoxic heart disease, and is normal.
Case scenario 5a -Initial presentation of a cat with cardiac disease
Application of the CURATIVE guidelines -Initial presentation
There is a strong association between feline cardiomyopathy, including hypertrophic obstructive cardiomyopathy, and thrombosis (Guideline 1.9a). This cat is thought to be at high risk for thrombosis given the left atrial dilation (Guidelines 1.9b ). As such, antithrombotic therapy is recommended (Guideline 1.9c) . The CURATIVE guidelines recommend that antiplatelet agents be used for the prevention of ATE in cats (Guideline 2.4a). Since cats with cardiomyopathy are at greater risk for ATE, rather than venous thromboembolism, an antiplatelet drug is recommended for this cat. Specifically, it is recommended that clopidogrel be used instead of aspirin in cats at risk of ATE (Guideline 2.6).
Clopidogrel at a dose of 18.75 mg PO once a day (one-quarter of a 75 mg tablet) is prescribed for the cat, with the intention of this being a life-long therapy since the underlying heart disease is not curable (Guideline 5.11). The clinician chose not to give a loading dose.
The owner is counselled regarding the clinical signs associated with the development of ATE and congestive heart failure. 16 Additionally, daily monitoring of sleeping and resting respiratory rates is instituted as a tool to assess for the development of heart failure. 17 An annual echocardiogram is planned to monitor the progression of heart disease.
Case scenario 5b -Subsequent presentation of a cat with cardiac disease and ATE
Eighteen months later the cat presents on an emergency basis with an acute onset of vocalizing and non-ambulatory paraplegia. Distal aortic thromboembolism was diagnosed based on the physical examination findings of pulseless, cold pelvic limbs. 18 The owner had been giving the clopidogrel daily since initial diagnosis. Analgesia is provided, and the cat is hospitalized for management of concurrent congestive heart failure. Oral clopidogrel is continued at 18.75 mg once daily.
Application of the CURATIVE guidelinesSubsequent presentation
Although no evidence-based recommendations can be made regarding the addition of anticoagulants to antiplatelet agents for the prevention of ATE in cats, the CURATIVE guidelines suggest the administration of clopidogrel in combination with LMWH can be considered in cats at risk of ATE (Guideline 2.20). As such, the clinician considered the addition of dalteparin or enoxaparin to the cat's treatment regimen.
The guidelines suggest that LMWHs (specifically, dalteparin and enoxaparin) should be given to cats by subcutaneous injection every 6 hours (Guidelines 3.10, 3.12) . The clinician should counsel the owners that bleeding complications can occur when using dalteparin in cats, although they are usually minor and self-limiting (Guideline is recommended to reduce inter-individual variation in peak anti-Xa activity. Examples of dosing considerations and cost comparisons for a one-month course of dalteparin versus enoxaparin for a cat is provided in Table 4 . Lifetime therapy with both clopidogrel and LMWH is recommended for this cat.
The LMWH doses for cats result in a very low volume to be administered. Most clinicians aliquot the contents of individual dosing syringes of dalteparin or enoxaparin into a sterile empty glass vial. The dose required for the cat can then be drawn up with a tuberculin syringe from the vial to ensure accurate dosing. Although not specifically covered in the CURATIVE guidelines, the addition of rivaroxaban to clopidogrel therapy could also be considered in this cat if LMWH dosing was not practical or the frequent injections were not feasible for the clients to undertake.
CONCLUSIONS
The CURATIVE guidelines provide the first consensus-based recommendations regarding the use of antithrombotic therapies in our dog and cat patients at risk of thrombosis. These guidelines are designed to aid the clinician in decision making; however, they do not negate the need for individualized patient care. These case scenarios highlight options for best practice in the field of antithrombotic therapy, with the hope of facilitating improved outcomes for dogs and cats at risk of thrombosis.
